Kromek Group PLC
KMK.UK
$0.09
Closing
▲7.14%
1D
▲56.25%
YTD
Market cap
$59.91M
52 week high
$0.11
52 week low
$0.04
Volume
2,237,457
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$59.91M
Analysts' Rating
-
Price Target (Mean)
0.315600778
Total Analysts
0
P/E
Operating Margin
-7.94%
Beta
1.41
Revenue Growth (Annual)
26.95%
52 week high
$0.11
52 week low
$0.04
Div. Yield
%
EPS Annual Growth
0.00
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Kromek Group plc is a developer of radiation detection and bio-detection technology solutions for the advanced imaging and chemical, biological, radiological, and nuclear (CBRN) detection segments. Its advanced imaging segment comprises the medical (including CT and SPECT), security, and industrial markets. The Company provides its original equipment manufacturer customers with detector components based on its core cadmium zinc telluride (CZT) platform. In CBRN detection, the Company provides nuclear radiation detection solutions to the global homeland defense and security market. Its compact, handheld, high-performance radiation detectors, based on advanced scintillation technology, are primarily used to protect critical infrastructure and urban environments from the threat of dirty bombs. The Company is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a range of airborne and liquid-based pathogens.
